{"classes":[{"categories":[{"measurements":[{"comment":"Percentage and 95 %Cl was not estimable due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Upper limit of 95 %Cl was not estimable due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"11.0","upperLimit":"NA","value":"15.9"}]}],"title":"TTCD for PF"},{"categories":[{"measurements":[{"comment":"Upper limit of 95 %Cl was not estimable due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"11.6","upperLimit":"NA","value":"12.9"},{"comment":"Upper limit of 95 %Cl was not estimable due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"7.6","upperLimit":"NA","value":"10.8"}]}],"title":"TTCD for GHS/QoL"}],"denoms":[{"counts":[{"groupId":"OG000","value":"241"},{"groupId":"OG001","value":"242"}],"units":"Participants"}],"description":"EORTC QLQ-C30=30 questions assessing 5 aspects of participant functioning(physical,emotional,role,cognitive \\&social),3 symptom scales,GHS/QoL \\& 6 single items.PF scale=5 questions about participants PF \\& daily activities(strenuous activities,long walks,short walks,bed/chair rest \\& needing help with eating,dressing,washing themselves/using the toilet).PF scale scored on 4-point scale(1=Not at All-4=Very Much).GHS/QoL scored on 7-point scale(1=Very Poor- 7=Excellent).Scores were linearly transformed to a range of 0-100,higher scores=higher response level \\& better QoL.TTCD for PF \\& GHS/QoL=time from the date of randomization until first confirmed clinically meaningful deterioration,which is decrease from baseline in PF/GHS score that must be held for at least 2 consecutive assessments/initial decrease above baseline followed by death attributable to cancer progression within 6 weeks of the last deteriorated assessment.Score change≥10-point change in subscale score,considered meaningful.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received atezolizumab, 1200 mg, Q3W as IV infusion on Day 1 of each 21-day cycle until unacceptable toxicity or PD whichever occurred first.","id":"OG000","title":"Atezolizumab"},{"description":"Participants received atezolizumab, 1200 mg, Q3W as IV infusion and lurbinectedin, 3.2 mg/m\\^2, Q3W as IV infusion on Day 1 of each 21-day cycle until unacceptable toxicity or PD whichever occurred first.","id":"OG001","title":"Atezolizumab+ Lurbinectedin"}],"paramType":"MEDIAN","populationDescription":"FAS included all participants randomized into the randomized phase, regardless of whether or not the assigned study treatment was received.","reportingStatus":"POSTED","timeFrame":"Up to 26 months","title":"Randomized Phase: Time to Confirmed Deterioration (TTCD) in Physical Functioning (PF) and Global Health Status (GHS) as Measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQC30)","type":"SECONDARY","unitOfMeasure":"months"}